{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:18Z","timestamp":1792979898603,"version":"4.5.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008212","name":"College of Medicine, Drexel University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004835","name":"Zhejiang University","doi-asserted-by":"publisher","award":["2023\\u20130182"],"award-info":[{"award-number":["2023\\u20130182"]}],"id":[{"id":"10.13039\/501100004835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jgar.2024.12.014","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T11:56:04Z","timestamp":1735300564000},"page":"151-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Potential drug interaction after withdrawal of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 infection"],"prefix":"10.1016","volume":"42","author":[{"given":"Yun","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglan","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3776-2290","authenticated-orcid":false,"given":"Zhenwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jgar.2024.12.014_bib0001","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2024.12.014_bib0002","first-page":"1290","article-title":"Paxlovid drug interaction screening checklist updated","volume":"328","author":"Larkin","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2024.12.014_bib0003","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin. Pharmacol. Ther"},{"key":"10.1016\/j.jgar.2024.12.014_bib0004","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/ajt.17027","article-title":"Early clinical experience with nirmatrelvir\/ritonavir for the treatment of COVID-19 in solid organ transplant recipients","volume":"22","author":"Salerno","year":"2022","journal-title":"Am. J. Transplant"},{"key":"10.1016\/j.jgar.2024.12.014_bib0005","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2174\/1389200218666170518165443","article-title":"Rivaroxaban - metabolism, pharmacologic properties and drug interactions","volume":"18","author":"Kvasnicka","year":"2017","journal-title":"Curr. Drug Metab."}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524004806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524004806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:59:18Z","timestamp":1762610358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524004806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":5,"alternative-id":["S2213716524004806"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.12.014","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential drug interaction after withdrawal of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}